So last CC it seemed like the company was moving ahead a lot of good directions. Maybe this board can again start being positive proactive with we have now and make suggestions on where we should go now.
I was wrong about thinking we would get an EUA with a CD17 trial no placebo and try the 4 dose or IV approach. What do people feel we should do now?
Jeff was right on the Macboob call. OK, but where do we go from here? What would this board like to see, no holds barred?